ARID3A

Across TCGA pan-cancer cohorts, ARID3A mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of ARID3A’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where ARID3A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ARID3A is over-expressed in tumor.

COAD, HNSC, and LSCC are the cancer types where ARID3A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARID3A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	III,IV	+1.029	<.001	12	view →
HNSC	Male	II,III,IV	+1.145	<.001	11	view →
LSCC	Male	III,IV	+0.739	<.001	8	view →
CCRCC	Male	All	+0.171	.027	6	view →
LUAD	Male	All	+0.348	<.001	5	view →
PDAC	Female	All	+1.183	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

ARID3A–COAD

Open the COAD breakdown →